

CLINICAL PHARMACOLOGY & THERAPEUTICS

EDITOR

Marcus M. Reidenberg, MD

FOUNDING EDITOR

Walter Modell, MD

ASSOCIATE EDITORS

Arthur J. Atkinson, Jr., MD
David W. Nierenberg, MD
Raymond L. Woosley, MD, PhD

ASSISTANT EDITOR

B. Robert Meyer, MD

MANAGING EDITOR

June Reidenberg

SENIOR MANUSCRIPT EDITOR

Connie Nelson

EDITORIAL BOARD

Darrell R. Abernethy, MD, PhD
Adedayo Adedoyin, PhD
Alvito P. Alvares, PhD
Matthew M. Ames, PhD
Fred Y. Aoki, MD
Larry A. Bauer, PharmD
Leif Bertilsson, PhD
Terrence F. Blaschke, MD
R. A. Branch, MD
Eric P. Brass, MD, PhD
D. Craig Brater, MD
Alastair Breckenridge, MSc, MD
Douwe D. Breimer, PhD
Michael E. Brier, PhD
James F. Burris, MD
S. George Carruthers, MD, FRCP
Dennis J. Chapron, RPh, MS
David M. Cocchetto, PhD
C. Lindsay DeVane, PharmD
Colin Dollery, MB, ChB, BSc
Margaret S. Dordal, MD, PhD
Akio Ebihara, MD
David J. Edwards, PharmD
Merrill J. Egorin, MD
William E. Evans, PharmD
Alvan R. Feinstein, MD

Ross D. Feldman, MD
Charles Flexner, MD
Marilynn C. Frederiksen, MD
Kathleen Giacomini, PhD
Jean Gray, MD, FRCP(C)
Linda E. Gustavson, PhD
Perry V. Halushka, MD, PhD
Thomas K. Henthorn, MD
Linda A. Hershey, MD, PhD
Peter H. Hinderling, MD
Takashi Ishizaki, MD
Patrice Jaillon, MD
William J. Jusko, PhD
Shigeru Kageyama, MD, PhD
Joan M. Korth-Bradley, PharmD, PhD
Belle L. Lee, PharmD
Juan J. Lertora, MD, PhD
Gerhard Levy, PharmD
David T. Lowenthal, MD, PhD
Carl V. Manion, MD
Lawrence G. Miller, MD, MPH
Edward B. Nelson, MD
Alan S. Nies, MD
Carl C. Peck, MD
Russell K. Portenoy, MD
William Z. Potter, MD, PhD
Mary V. Relling, PharmD
Nancy C. Sambol, PharmD
Jerome J. Schentag, PharmD
Edward M. Sellers, MD, PhD, FRCP(C)
Steven L. Shafer, MD
Lewis B. Sheiner, MD
Alexander M. M. Shepherd, MD, PhD
Daniel S. Sitar, PhD
Folke Sjöqvist, MD
Cedric M. Smith, MD
Donald R. Stanski, MD
Arnold B. Stermann, MD
John T. Sullivan, MB, ChB, FRACP
Robert Temple, MD
Elliot S. Vesell, MD
Robert E. Vestal, MD
John B. Warren, MD, FRCP
William B. White, MD
Thomas L. Whitsett, MD
Grant R. Wilkinson, PhD
John T. Wilson, MD
Alastair J. J. Wood, MB, ChB

VOLUME 64, JULY-DECEMBER 1998
MOSBY, INC., ST. LOUIS

CLINICAL PHARMACOLOGY & THERAPEUTICS

Official Publication of the
American Society for Clinical Pharmacology and Therapeutics
American Society for Pharmacology and Experimental Therapeutics

EDITORIAL ADVISORY COMMITTEE FOR THE JOURNAL

Jeffrey L. Blumer, PhD, MD, Cleveland, Ohio (ASCPT)
D. Craig Brater, MD, Indianapolis, Ind. (ASPET)
James W. Gibb, PhD, Salt Lake City, Utah (ASCPT)
Perry V. Halushka, PhD, MD, Charleston, S.C. (ASPET)
Janice B. Schwartz, MD, Chicago, Ill. (ASPET)
Andre Terzic, MD, PhD Rochester, Minn. (ASCPT)

MEMBERS OF THE COUNCIL OF THE AMERICAN SOCIETY FOR PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

President: Kenneth E. Moore, PhD, East Lansing, Mich.
President-Elect: Jerry E. Mitchell, MD, PhD, Research Triangle Park, N.C.
Secretary-Treasurer: Brian M. Cox, PhD, Bethesda, Md.
Chair, Board of Publications Trustees: T. Kendall Harden, PhD, Chapel Hill, N.C.
Executive Officer: Christine K. Carrico, PhD

OFFICERS OF THE AMERICAN SOCIETY FOR CLINICAL PHARMACOLOGY AND THERAPEUTICS

President: Carl C. Peck, MD, Washington, D.C.
President-Elect: Jean D. Gray, MD, FRCP(C), Halifax, Nova Scotia, Canada
Secretary-Treasurer: John J. Schrogie, MD, Philadelphia, Pa.
Chair, Publications Committee: Robert Z. Gussin, PhD, New Brunswick, N.J.
Executive Director (Acting): Denise Gavetti, Conshohocken, Pa.

Volume 64
Copyright © 1998 by
Mosby, Inc.
All rights reserved
Printed in the United States of America

Index to volume 64

Author index

A

- Abdi YA (*see* Herrlin et al). 1998;64:391-401
 Abernethy DR, Woosley RL. 1999 ASCPT Clinical Pharmacology Curriculum Review Course. 1998;64:694
 Abernethy DR (*see* Trapnell et al). 1998;64:597-602
 Acosta EP (*see* Fletcher et al). 1998;64:331-8
 Adedoyin A, Arms PA, Richards WO, Wilkinson GR, Branch RA. Selective effect of liver disease on the activities of specific metabolizing enzymes: investigation of cytochromes P450 2C19 and 2D6. 1998;64:8-17
 Allain H (*see* Rosenzweig et al). 1998;64:211-22
 Allain H (*see* Siproudhis et al). 1998;64:424-32
 Alm C (*see* Arlander et al). 1998;64:484-9
 Alm C (*see* Herrlin et al). 1998;64:391-401
 Anasetti C (*see* Ren et al). 1998;64:289-301
 Anello C (*see* D'Agostino et al). 1998;64:579-96 (Commentary)
 Angst MS, Dyck JB, Azarnoff DL, Goldblum R, Ho B, Gfroerer T, Linton EA, Glynn BP, Shafer SL. Pharmacokinetics, cortisol release, and hemodynamics after intravenous and subcutaneous injection of human corticotropin-releasing factor in humans. 1998;64:499-51
 Anttila M (*see* Kivistö et al). 1998;64:648-54
 Anttila M (*see* Scheinin et al). 1998;64:402-11
 Appelbaum FR (*see* Ren et al). 1998;64:289-301
 Arlander E, Ekström G, Alm C, Carrillo JA, Bielenstein M, Böttiger Y, Bertilsson L, Gustafsson LL. Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: an interaction study with flvoxamine and ketoconazole as in vivo inhibitors. 1998;64:484-9
 Armellino J (*see* Migliardi et al). 1998;64:465-6 (Letter)
 Arms PA (*see* Adedoyin et al). 1998;64:8-17
 Ashton M (*see* Svensson et al). 1998;64:160-7
 Azarnoff DL (*see* Angst et al). 1998;64:499-51
 Azie NE, Brater DC, Becker PA, Jones DR, Hall SD. The interaction of diltiazem with lovastatin and pravastatin. 1998;64:369-77

B

- Baas H (*see* Harder and Baas). 1998;64:183-91
 Backman JT (*see* Lilja et al). 1998;64:655-60
 Badr S (*see* Major et al). 1998;64:450-61
 Bahlawan L (*see* Major et al). 1998;64:450-61
 Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR. Grapefruit juice-felodipine interaction: effect of naringin and 6',7'-dihydroxybergamottin in humans. 1998;64:248-56
 Balfour HH Jr (*see* Fletcher et al). 1998;64:331-8
 Barbanjo MJ, Parra P, Jané F. Buspirone plasma concentrations. 1998;64:347 (Letter)
 Barbey JT (*see* Yasuda et al). 1998;64:536-41
 Baseler M (*see* Piscitelli et al). 1998;64:492-8
 Baweja RK (*see* Mahmood et al). 1998;64:547-52
 Baxter PJ (*see* Kharasch et al). 1998;64:39-45
 Beaver W (*see* Migliardi et al). 1998;64:465-6 (Letter)
 Beck DJ (*see* Kashuba et al). 1998;64:257-68

- Beck DJ (*see* Kashuba et al). 1998;64:269-77
 Becker PA (*see* Azie et al). 1998;64:369-77
 Bellissant E (*see* Siproudhis et al). 1998;64:424-32
 Bend JR (*see* Bailey et al). 1998;64:248-56
 Benetos A (*see* Lafleche et al). 1998;64:96-105
 Benowitz NL (*see* Zevin et al). 1998;64:87-95
 Benton RE (*see* Yasuda et al). 1998;64:536-41
 Bertilsson L (*see* Arlander et al). 1998;64:484-9
 Bertilsson L (*see* Herrlin et al). 1998;64:391-401
 Bertilsson L (*see* Scheinin et al). 1998;64:402-11
 Bertilsson L (*see* Svensson et al). 1998;64:160-7
 Bertilsson L (*see* Yue et al). 1998;64:384-90
 Bertino JS Jr (*see* Kashuba et al). 1998;64:257-68
 Bertino JS Jr (*see* Kashuba et al). 1998;64:269-77
 Besson J (*see* Eap et al). 1998;64:52-7
 Bhargava VK (*see* Garg et al). 1998;64:286-8
 Bielenstein M (*see* Arlander et al). 1998;64:484-9
 Billard V (*see* Gambús et al). 1998;64:27-38
 Blazer DG (*see* Hanlon et al). 1998;64:684-92
 Bondesson U (*see* Rasmussen et al). 1998;64:150-9
 Böttiger Y (*see* Arlander et al). 1998;64:484-9
 Bowen JD, Petersdorf SH, Richards TL, Maravilla KR, Dale DC, Price TH, St John TP, Yu AS. Phase I study of a humanized anti-CD11/CD18 monoclonal antibody in multiple sclerosis. 1998;64:339-46
 Branch RA. Drugs in liver disease. 1998;64:462-5 (Letter)
 Branch RA (*see* Adedoyin et al). 1998;64:8-17
 Brater DC (*see* Azie et al). 1998;64:369-77
 Breckenridge A (*see* Reidenberg and Breckenridge). 1998;64:353-4 (Commentary)
 Breidenbach T (*see* Kovarik et al). 1998;64:66-72
 Bretagne JF (*see* Siproudhis et al). 1998;64:424-32
 Brose WG (*see* Gambús et al). 1998;64:27-38
 Brown MC. Interaction between warfarin and 5-fluorouracil, not between warfarin and levamisole. 1998;64:233 (Letter)
 Brune K (*see* Levy et al). 1998;64:117-22
 Buclin T (*see* Eap et al). 1998;64:52-7
 Bullingham RES (*see* Hale et al). 1998;64:672-83
 Burggraaf J (*see* van Haarst et al). 1998;64:542-6
 Burkell J (*see* Swartzman and Burkell). 1998;64:1-7 (Commentary)

C

- Cantilena LR Jr (*see* D'Agostino et al). 1998;64:579-96 (Commentary)
 Caraco Y (*see* Levy et al). 1998;64:117-22
 Carlson G (*see* Ouellet et al). 1998;64:355-62
 Carrillo JA (*see* Arlander et al). 1998;64:484-9
 Carstens J, Jensen KT, Pedersen EB. Metabolism and action of urodelatin infusion in healthy volunteers. 1998;64:73-86
 Cavanaugh J (*see* Ouellet et al). 1998;64:355-62
 Cevallos WH (*see* Greenblatt et al). 1998;64:553-61
 Chaitt D (*see* Piscitelli et al). 1998;64:492-8
 Chan CK (*see* Kumana et al). 1998;64:569-74
 Cheung E (*see* Kumana et al). 1998;64:569-74
 Cheung WK, Goon BL, Guilfoyle MC, Wacholtz MC. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects. 1998;64:412-23
 Ching TY (*see* Kumana et al). 1998;64:569-74

July, pp. 1-132; August, pp. 133-236; September, pp. 237-352; October, pp. 353-470; November, pp. 471-578; December, pp. 579-714. Index to the ASCPT meeting abstracts is located in the February issue.

Chompoonawee S, Nunthapisud P, Trivijitsilp P, Sentrakul P, Dusitsin N. The use of two estrogen preparations (a combined contraceptive pill versus conjugated estrogen cream) intravaginally to treat urogenital symptoms in postmenopausal Thai women: a comparative study. 1998;64:204-10

Chu KM (*see* Kumana et al). 1998;64:569-74
Cimarosti I (*see* Rosenzweig et al). 1998;64:211-22
Coene MC (*see* van Haarst et al). 1998;64:542-6
Cohen AF (*see* van Haarst et al). 1998;64:542-6
Cohen HJ (*see* Hanlon et al). 1998;64:684-92
Cohen O (*see* Levy et al). 1998;64:117-22
Collins JM (*see* Trapnell et al). 1998;64:597-602
Cöng LD (*see* Svensson et al). 1998;64:160-7
Corbett K (*see* Greenblatt et al). 1998;64:237-47
Corbett K (*see* Greenblatt et al). 1998;64:553-61
Coulmel P (*see* Lande et al). 1998;64:312-21
Counihan M (*see* Greenblatt et al). 1998;64:237-47
Counihan M (*see* Greenblatt et al). 1998;64:278-85
Counihan M (*see* Greenblatt et al). 1998;64:553-61
Counihan M (*see* Greenblatt et al). 1998;64:661-71
Coutinho EM (*see* de Lourdes Pires Nascimento et al). 1998;64:433-8

D

D'Agostino RB Jr (*see* D'Agostino et al). 1998;64:579-96 (Commentary)
D'Agostino RB Sr, Weintraub M, Russell HK, Stepanians M, D'Agostino RB Jr, Cantilena LR Jr, Graumlich JF, Maldonado S, Honig P, Anello C. The effectiveness of antihistamines in reducing the severity of runny nose and sneezing: a meta-analysis. 1998;64:579-96 (Commentary)
Dahl ML (*see* Herrlin et al). 1998;64:391-401
Dahl ML (*see* Scheinin et al). 1998;64:402-11
Dahl ML (*see* Yue et al). 1998;64:384-90
Dale DC (*see* Bowen et al). 1998;64:339-46
Dalén P (*see* Yue et al). 1998;64:384-90
Darwish M (*see* Greenblatt et al). 1998;64:553-61
Davey RT (*see* Piscitelli et al). 1998;64:492-8
Davies RA (*see* Leenen et al). 1998;64:522-35
de Alwis DP (*see* Hempel et al). 1998;64:622-35
de Lourdes Pires Nascimento M, Ladipo OA, Coutinho EM. Norgestrel acetate contraceptive implant use by women with sickle cell disease. 1998;64:433-8
Desager JP (*see* Leclercq et al). 1998;64:144-9
Dionne RA, Max MB, Gordon SM, Parada S, Sang C, Gracely RH, Sethna NF, MacLean DB. The substance P receptor antagonist CP-99,994 reduces acute postoperative pain. 1998;64:562-8
Dobrev D (*see* Grossmann et al). 1998;64:302-11
Donahue SR (*see* Trapnell et al). 1998;64:597-602
Dorner GT, Selenko N, Kral T, Schmetterer L, Eichler HG, Wolzt M. Hemodynamic effects of continuous urotilatin infusion: a dose-finding study. 1998;64:322-30
Douyon E (*see* Yasuda et al). 1998;64:536-41
Duan SX (*see* Greenblatt et al). 1998;64:278-85
Durol ALB (*see* Greenblatt et al). 1998;64:278-85
Durol ALB (*see* Greenblatt et al). 1998;64:661-71
Dusitsin N (*see* Chompoonawee et al). 1998;64:204-10
Dyck JB (*see* Angst et al). 1998;64:499-51

E

Eap CB, Schnyder C, Besson J, Savary L, Buclin T. Inhibition of CYP2E1 by chlormethiazole as measured by chlorzoxazone pharmacokinetics in patients with alcoholism and in healthy volunteers. 1998;64:52-7
Ehrenberg BL (*see* Greenblatt et al). 1998;64:237-47
Ehrenberg BL (*see* Greenblatt et al). 1998;64:553-61
Eichler HG (*see* Dorner et al). 1998;64:322-30
Ekström G (*see* Arlander et al). 1998;64:484-9

Eric A (*see* Fletcher et al). 1998;64:331-8
Eriksson B (*see* Rasmussen et al). 1998;64:150-9
Evans WE (*see* Loennechen et al). 1998;64:46-51

F

Fayn J (*see* Lande et al). 1998;64:312-21
Fessing MY (*see* Loennechen et al). 1998;64:46-51
Fillenbaum GG (*see* Hanlon et al). 1998;64:684-92
Fletcher CV, Acosta EP, Henry K, Page LM, Gross CR, Kawle SP, Remmel RP, Eric A, Balfour HH Jr. Concentration-controlled zidovudine therapy. 1998;64:331-8
Flockhart DA (*see* Trapnell et al). 1998;64:597-602
Forrest A (*see* Piscitelli et al). 1998;64:492-8
Fourney A (*see* Leenen et al). 1998;64:522-35
Freeman DJ (*see* Bailey et al). 1998;64:248-56
Fujii H (*see* Minami et al). 1998;64:511-21
Funck-Brentano C (*see* Lande et al). 1998;64:312-21
Funck-Brentano C (*see* Ragueneau et al). 1998;64:192-203
Futami T (*see* Wakasugi et al). 1998;64:123-8

G

Gabrielsson J (*see* von Bahr et al). 1998;64:18-26
Gambús PL, Schnider TW, Minto CF, Youngs EJ, Billard V, Brose WG, Hochhaus G, Shafer SL. Pharmacokinetics of intravenous dynorphin A(1-13) in opioid-naïve and opioid-treated human volunteers. 1998;64:27-38
Gandon JM (*see* Rosenzweig et al). 1998;64:211-22
Garg SK, Kumar N, Bhargava VK, Prabhakar SK. Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy. 1998;64:286-8
Gautier S (*see* Lafleche et al). 1998;64:96-105
Geisslinger G (*see* Levy et al). 1998;64:117-22
Geisslinger G (*see* Scheuerer et al). 1998;64:168-76
Gerbeau C (*see* Kovarik et al). 1998;64:66-72
Gfroerer T (*see* Angst et al). 1998;64:499-51
Ghadanfar M (*see* Lande et al). 1998;64:312-21
Gillings DB (*see* Migliardi et al). 1998;64:465-6 (Letter)
Girerd X (*see* Lafleche et al). 1998;64:96-105
Glynn BP (*see* Angst et al). 1998;64:499-51
Goldblum R (*see* Angst et al). 1998;64:499-51
Goon BL (*see* Cheung et al). 1998;64:412-23
Gordin A (*see* Trocóniz et al). 1998;64:106-16
Gordon SM (*see* Dionne et al). 1998;64:562-8
Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O'Mara EM Jr, Hall SD. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. 1998;64:133-43
Gosselin M (*see* Siproudhis et al). 1998;64:424-32
Gotschall R (*see* Kashuba et al). 1998;64:257-68
Gracely RH (*see* Dionne et al). 1998;64:562-8
Graf JA (*see* Greenblatt et al). 1998;64:278-85
Graf JA (*see* Greenblatt et al). 1998;64:553-61
Graf JA (*see* Greenblatt et al). 1998;64:661-71
Granneman GR (*see* Ouellet et al). 1998;64:355-62
Graumlich JF (*see* D'Agostino et al). 1998;64:579-96 (Commentary)
Greenblatt DJ, Harmatz JS, von Moltke LL, Ehrenberg BL, Harrel L, Corbett K, Counihan M, Graf JA, Darwish M, Mertzanis P, Martin PT, Cevallos WH, Shader RI. Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo. 1998;64:553-61
Greenblatt DJ, von Moltke LL, Harmatz JS, Counihan M, Graf JA, Durol ALB, Mertzanis P, Duan SX, Wright CE, Shader RI. Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences. 1998;64:278-85
Greenblatt DJ, von Moltke LL, Harmatz JS, Mertzanis P, Graf JA, Durol ALB, Counihan M, Roth-Schechter B, Shader RI. Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole. 1998;64:661-71

- Greenblatt DJ, Wright CE, von Moltke LL, Harmatz JS, Ehrenberg BL, Harrel LM, Corbett K, Counihan M, Tobias S, Shader RI. Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. 1998;64:237-47
- Gross CR (see Fletcher et al). 1998;64:331-8
- Grossmann M, Dobrev D, Kirch W. Amiodarone causes endothelium-dependent vasodilation in human hand veins in vivo. 1998;64:302-11
- Guenther H (see Ouellet et al). 1998;64:355-62
- Guilfoyle MC (see Cheung et al). 1998;64:412-23
- Gustafsson LL (see Arlander et al). 1998;64:484-9
- Gustafsson LL (see Herrlin et al). 1998;64:391-401

H

- Haehner-Daniels BD (see Gorski et al). 1998;64:133-43
- Hai TN (see Svensson et al). 1998;64:160-7
- Hale MD, Nicholls AJ, Bullingham RES, Hené R, Hoitsma A, Squifflet JP, Weimar W, Vanrenterghem Y, Van de Woude FJ, Verpooten GA. The pharmacokinetic/pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. 1998;64:672-83
- Hall SD (see Azie et al). 1998;64:369-77
- Hall SD (see Gorski et al). 1998;64:133-43
- Hall SD (see Scheuerer et al). 1998;64:168-76
- Hamman MA (see Gorski et al). 1998;64:133-43
- Hammarlund-Udenaes M (see Olsson Gislekog et al). 1998;64:636-47
- Hankins DG (see Kharasch et al). 1998;64:39-45
- Hanlon JT, Horner RD, Schmader KE, Fillenbaum GG, Lewis IK, Wall WE Jr, Landerman LR, Pieper CF, Blazer DG, Cohen HJ. Benzodiazepine use and cognitive function among community-dwelling elderly. 1998;64:684-92
- Harder S, Baas H. Concentration-response relationship of levodopa in patients at different stages of Parkinson's disease. 1998;64:183-91
- Harmatz JS (see Greenblatt et al). 1998;64:237-47
- Harmatz JS (see Greenblatt et al). 1998;64:278-85
- Harmatz JS (see Greenblatt et al). 1998;64:553-61
- Harmatz JS (see Greenblatt et al). 1998;64:661-71
- Harrel L (see Greenblatt et al). 1998;64:553-61
- Harrel LM (see Greenblatt et al). 1998;64:237-47
- Hashida T (see Wakasugi et al). 1998;64:123-8
- Hassan G (see Major et al). 1998;64:450-61
- Heiskanen T, Olkkola KT, Kalso E. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. 1998;64:603-11
- Hempel G, Karlsson MO, de Alwis DP, Toubanc N, McNay J, Schaefer HG. Population pharmacokinetic-pharmacodynamic modeling of moxonidine with 24-hour ambulatory blood pressure measurements. 1998;64:622-35
- Hené R (see Hale et al). 1998;64:672-83
- Henry K (see Fletcher et al). 1998;64:331-8
- Hermann D (see Olsson Gislekog et al). 1998;64:636-47
- Herrlin K, Massele AY, Jande M, Alm C, Tybring G, Abdi YA, Wennerholm A, Johansson I, Dahl ML, Bertilsson L, Gustafsson LL. Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their *CYP2C19* genotype. 1998;64:391-401
- Hettiarachchi J (see Wallis et al). 1998;64:439-49
- Ho B (see Angst et al). 1998;64:499-51
- Hochhaus G (see Gambús et al). 1998;64:27-38
- Hoitsma A (see Hale et al). 1998;64:672-83
- Honig P (see D'Agostino et al). 1998;64:579-96 (Commentary)
- Horner RD (see Hanlon et al). 1998;64:684-92
- Horsmans Y (see Leclercq et al). 1998;64:144-9
- Hsu A (see Ouellet et al). 1998;64:355-62
- Huong DX (see Svensson et al). 1998;64:160-7

I

- Igarashi T (see Minami et al). 1998;64:511-21
- Inui K-i (see Wakasugi et al). 1998;64:123-8
- Ito T (see Wakasugi et al). 1998;64:123-8
- Itoh K (see Minami et al). 1998;64:511-21

J

- Jacob P III (see Zevin et al). 1998;64:87-95
- Jaillon P (see Ragueneau et al). 1998;64:192-203
- Jande M (see Herrlin et al). 1998;64:391-401
- Jané F (see Barbanoj et al). 1998;64:347 (Letter)
- Jara H (see Lechin et al). 1998;64:223-32
- Jensen KT (see Carstens et al). 1998;64:73-86
- Jochimsen R (see Ragueneau et al). 1998;64:192-203
- Johansson I (see Herrlin et al). 1998;64:391-401
- Jones DR (see Azie et al). 1998;64:369-77
- Jones DR (see Gorski et al). 1998;64:133-43
- Juguet F (see Siproudhis et al). 1998;64:424-32

K

- Kalhorn TF (see Ren et al). 1998;64:289-301
- Kalso E (see Heiskanen et al). 1998;64:603-11
- Kantola T, Kivistö KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics of atorvastatin. 1998;64:58-65
- Kantola T, Kivistö KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. 1998;64:177-82
- Kantola T (see Kivistö et al). 1998;64:347-8 (Letter reply)
- Karlsson MO (see Olsson Gislekog et al). 1998;64:636-47
- Karlsson MO (see Hempel et al). 1998;64:622-35
- Karlsson MO (see Trocóniz et al). 1998;64:106-16
- Karnani H (see Scheinin et al). 1998;64:402-11
- Kashuba ADM, Bertino JS Jr, Rocci ML Jr, Kulawy RW, Beck DJ, Nafziger AN. Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam. 1998;64:269-77
- Kashuba ADM, Nafziger AN, Kearns GL, Leeder JS, Gotschall R, Rocci ML Jr, Kulawy RW, Beck DJ, Bertino JS Jr. Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping. 1998;64:257-68
- Kaukonen KM (see Varis et al). 1998;64:363-8
- Kawle SP (see Fletcher et al). 1998;64:331-8
- Kearns GL (see Kashuba et al). 1998;64:257-68
- Khalil R (see Major et al). 1998;64:450-61
- Kharasch ED, Hankins DG, Baxter PJ, Thummel KE. Single-dose disulfiram does not inhibit CYP2A6 activity. 1998;64:39-45
- Khogali M (see Major et al). 1998;64:450-61
- Khogaoghanian T (see Major et al). 1998;64:450-61
- Kirch W (see Grossmann et al). 1998;64:302-11
- Kivistö KT, Lamberg TS, Kantola T, Neuvonen PJ. Buspirone plasma concentrations. 1998;64:347-8 (Letter reply)
- Kivistö KT, Villikka K, Nyman L, Anttila M, Neuvonen PJ. Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin. 1998;64:648-54
- Kivistö KT (see Kantola et al). 1998;64:58-65
- Kivistö KT (see Kantola et al). 1998;64:177-82
- Kivistö KT (see Lilja et al). 1998;64:477-83
- Kivistö KT (see Lilja et al). 1998;64:655-60
- Kivistö KT (see Varis et al). 1998;64:363-8
- Kohli KK. How to correctly calculate the proportions of the heterozygotes and homozygotes in the extensive metabolizers of a certain drug-metabolizing enzyme in an ethnic or racial population? 1998;64:575 (Letter reply)
- Koike Y (see von Bahr et al). 1998;64:18-26
- Kong Y (see Kumana et al). 1998;64:569-74

- Korn A (see Kovarik et al). 1998;64:66-72
Kou M (see Kumana et al). 1998;64:569-74
Kovacs JA (see Piscitelli et al). 1998;64:492-8
Kovarik J, Breidenbach T, Gerbeau C, Korn A, Schmidt A-G, Nashan B. Disposition and immunodynamics of basiliximab in liver allograft recipients. 1998;64:66-72
Kral T (see Dörner et al). 1998;64:322-30
Kreeft JH (see Bailey et al). 1998;64:248-56
Krynetski EY (see Loennechen et al). 1998;64:46-51
Kulawy RW (see Kashuba et al). 1998;64:257-68
Kulawy RW (see Kashuba et al). 1998;64:269-77
Kumana CR, Ching TY, Cheung E, Kong Y, Kou M, Chan CK, Chu KM, Seto WH, Lam SK. Antiulcer drug prescribing in hospital successfully influenced by "immediate concurrent feedback". 1998;64:569-74
Kumar N (see Garg et al). 1998;64:286-8

L

- Ladipo OA (see de Lourdes Pires Nascimento et al). 1998;64:433-8
Lafleche A, Gautier S, Topouchian J, Wilmet CS, Girerd X, Safar ME, Benetos A. Differential responses of the heart and vasculature to chronic blood pressure reduction in essential hypertension. 1998;64:96-105
Lam SK (see Kumana et al). 1998;64:569-74
Lamberg TS (see Kivistö et al). 1998;64:347-8 (Letter reply)
Lamberg TS (see Lilja et al). 1998;64:655-60
Lande G, Maison-Blanche P, Fayn J, Ghadanfar M, Coumel P, Funck-Brentano C. Dynamic analysis of dofetilide-induced changes in ventricular repolarization. 1998;64:312-21
Landerman LR (see Hanlon et al). 1998;64:684-92
Laveille C (see Ragueneau et al). 1998;64:192-203
Lechin AE (see Lechin et al). 1998;64:223-32
Lechin F, van der Dijs B, Orozco B, Jara H, Rada I, Lechin ME, Lechin AE. Neuropsychopharmacologic treatment of bronchial asthma with the antidepressant tianeptine: a double-blind, crossover placebo-controlled study. 1998;64:223-32
Lechin ME (see Lechin et al). 1998;64:223-32
Leclercq I, Desager JP, Horsmans Y. Inhibition of chlorzoxazone metabolism, a clinical probe for CYP2E1, by a single ingestion of watercress. 1998;64:144-9
Leeder JS (see Kashuba et al). 1998;64:257-68
Leenen FHH, Davies RA, Fournay A. Catecholamines and heart function in heart transplant patients: effects of β_1 - versus nonselective β -blockade. 1998;64:522-35
Leonard JM (see Ouellet et al). 1998;64:355-62
Levy M, Brune K, Zylber-Katz E, Cohen O, Caraco Y, Geisslinger G. Cerebrospinal fluid prostaglandins after systemic dipyron intake. 1998;64:117-22
Lewis IK (see Hanlon et al). 1998;64:684-92
Lilja JJ, Kivistö KT, Backman JT, Lamberg TS, Neuvonen PJ. Grapefruit juice substantially increases plasma concentrations of buspirone. 1998;64:655-60
Lilja JJ, Kivistö KT, Neuvonen PJ. Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. 1998;64:477-83
Linton EA (see Angst et al). 1998;64:499-51
Loennechen T, Yates CR, Fessing MY, Relling MV, Krynetski EY, Evans WE. Isolation of a human thiopurine S-methyltransferase (TPMT) complementary DNA with a single nucleotide transition A719G (TPMT*3C) and its association with loss of TPMT protein and catalytic activity in humans. 1998;64:46-51
Lykkesfeldt J (see Svensson et al). 1998;64:160-7

M

- MacLean DB (see Dionne et al). 1998;64:562-8
Mahmood I, Tammara VK, Baweja RK. Does percent reduction in seizure frequency correlate with plasma concentration of anticonvulsant drugs? experience with four anticonvulsant drugs. 1998;64:547-52
Maison-Blanche P (see Lande et al). 1998;64:312-21
Major S, Badr S, Bahlawan L, Hassan G, Khogaghlanian T, Khalil R, Melhem A, Richani R, Younes F, Yeretizian J, Khogali M, Sabra R. Drug-related hospitalization at a tertiary teaching center in Lebanon: incidence, associations, and relation to self-medicating behavior. 1998;64:450-61
Maldonado S (see D'Agostino et al). 1998;64:579-96 (Commentary)
Maravilla KR (see Bowen et al). 1998;64:339-46
Martin PT (see Greenblatt et al). 1998;64:553-61
Massele AY (see Herrlin et al). 1998;64:391-401
Max MB (see Dionne et al). 1998;64:562-8
McDonald GB (see Ren et al). 1998;64:289-301
McNay J (see Hempel et al). 1998;64:622-35
Melhem A (see Major et al). 1998;64:450-61
Mertzanis P (see Greenblatt et al). 1998;64:278-85
Mertzanis P (see Greenblatt et al). 1998;64:553-61
Mertzanis P (see Greenblatt et al). 1998;64:661-71
Metcalfe J (see Piscitelli et al). 1998;64:492-8
Migliardi JR, Armellino J, Beaver W, Gillings DB. Caffeine in tension headache. 1998;64:465-6 (Letter)
Minami H, Sasaki Y, Saijo N, Ohtsu T, Fujii H, Igarashi T, Itoh K. Indirect-response model for the time course of leukopenia with anticancer drugs. 1998;64:511-21
Minto CF (see Gambús et al). 1998;64:27-38
Munoz C (see Bailey et al). 1998;64:248-56

N

- Nafziger AN (see Kashuba et al). 1998;64:257-68
Nafziger AN (see Kashuba et al). 1998;64:269-77
Nagashima S (see Yasuda et al). 1998;64:536-41
Nashan B (see Kovarik et al). 1998;64:66-72
Naukkarinen TH (see Trocóniz et al). 1998;64:106-16
Neuvonen PJ (see Kantola et al). 1998;64:58-65
Neuvonen PJ (see Kantola et al). 1998;64:177-82
Neuvonen PJ (see Kivistö et al). 1998;64:347-8 (Letter reply)
Neuvonen PJ (see Kivistö et al). 1998;64:648-54
Neuvonen PJ (see Lilja et al). 1998;64:477-83
Neuvonen PJ (see Lilja et al). 1998;64:655-60
Neuvonen PJ (see Varis et al). 1998;64:363-8
Nicholls AJ (see Hale et al). 1998;64:672-83
Nièu NT (see Svensson et al). 1998;64:160-7
Nohara R (see Wakasugi et al). 1998;64:123-8
Nowak MP, Sellers EM, Tyndale RF. Canadian Native Indians exhibit unique CYP2A6 and CYP2C19 mutant allele frequencies. 1998;64:378-83
Nunthapissud P (see Chompotaweep et al). 1998;64:204-10
Nyman L (see Kivistö et al). 1998;64:648-54
Nyman L (see Scheinin et al). 1998;64:402-11

O

- Öberg K (see Rasmussen et al). 1998;64:150-9
Ohtsu T (see Minami et al). 1998;64:511-21
Olkkola KT (see Heiskanen et al). 1998;64:603-11
Olsson Gisleskog PO, Hermann D, Hammarlund-Udenaes M, Karlsson MO. A model for the turnover of dihydrotestosterone in the presence of the irreversible 5 α -reductase inhibitors G1198745 and finasteride. 1998;64:636-47
O'Mara EM Jr (see Gorski et al). 1998;64:133-43
Orozco B (see Lechin et al). 1998;64:223-32

Ouellet D, Hsu A, Granneman GR, Carlson G, Cavanaugh J, Guenther H, Leonard JM. Pharmacokinetic interaction between ritonavir and clarithromycin. 1998;64:355-62

P

Page LM (see Fletcher et al). 1998;64:331-8
Parada S (see Dionne et al). 1998;64:562-8
Parra P (see Barbanj et al). 1998;64:347 (Letter)
Patat A (see Rosenzweig et al). 1998;64:211-22
Peck CC. A message from the President: the Centennial ASCPT meeting—come to San Antonio, March 18-20, 1999. 1998;64:693-4
Pedersen EB (see Carstens et al). 1998;64:73-86
Pelkonen O (see Scheinin et al). 1998;64:402-11
Petersdorf SH (see Bowen et al). 1998;64:339-46
Pieper CF (see Hanlon et al). 1998;64:684-92
Piscitelli SC, Forrest A, Vogel S, Chait D, Metcalf J, Stevens R, Baseler M, Davey RT, Kovacs JA. Pharmacokinetic modeling of recombinant interleukin-2 in patients with human immunodeficiency virus infection. 1998;64:492-8
Prabhakar SK (see Garg et al). 1998;64:286-8
Price TH (see Bowen et al). 1998;64:339-46

R

Rada I (see Lechin et al). 1998;64:223-32
Ragueneau I, Laveille C, Jochemsen R, Resplandy G, Funck-Brentano C, Jaillon P. Pharmacokinetic-pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers. 1998;64:192-203
Ramsay LE (see Wallis et al). 1998;64:439-49
Rane A (see Rasmussen et al). 1998;64:150-9
Rasmussen E, Eriksson B, Öberg K, Bondesson U, Rane A. Selective effects of somatostatin analogs on human drug-metabolizing enzymes. 1998;64:150-9
Reidenberg MM. Drugs in liver disease. 1998;64:465 (Letter reply)
Reidenberg MM, Breckenridge A. Drugs and the liver. 1998;64:353-4 (Commentary)
Relling MV (see Loennechen et al). 1998;64:46-51
Rommel RP (see Fletcher et al). 1998;64:331-8
Ren S, Kalhorn TF, McDonald GB, Anasetti C, Appelbaum FR, Slattery JT. Pharmacokinetics of cyclophosphamide and its metabolites in bone marrow transplantation patients. 1998;64:289-301
Resplandy G (see Ragueneau et al). 1998;64:192-203
Richani R (see Major et al). 1998;64:450-61
Richards TL (see Bowen et al). 1998;64:339-46
Richards WO (see Adedoyin et al). 1998;64:8-17
Rinne UK (see Trocóniz et al). 1998;64:106-16
Rocci ML Jr (see Kashuba et al). 1998;64:257-68
Rocci ML Jr (see Kashuba et al). 1998;64:269-77
Rosenzweig P, Patat A, Zieleniuk I, Cimarosti I, Allain H, Gandon JM. Cognitive performance in elderly subjects after a single dose of befloxtone, a new reversible selective monoamine oxidase A inhibitor. 1998;64:211-22
Roth-Schechter B (see Greenblatt et al). 1998;64:661-71
Ruottinen HM (see Trocóniz et al). 1998;64:106-16
Russell HK (see D'Agostino et al). 1998;64:579-96 (Commentary)
Russell T, Stoltz M, Weir S. Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers. 1998;64:612-21

S

Sabra R (see Major et al). 1998;64:450-61
Safar ME (see Lafleche et al). 1998;64:96-105
Saijo N (see Minami et al). 1998;64:511-21
St. John TP (see Bowen et al). 1998;64:339-46
Sang C (see Dionne et al). 1998;64:562-8

Sasaki Y (see Minami et al). 1998;64:511-21
Sasayama S (see Wakasugi et al). 1998;64:123-8
Savary L (see Eap et al). 1998;64:52-7
Schaefer HG (see Hempel et al). 1998;64:622-35
Scheinin H, Anttila M, Dahl ML, Karnani H, Nyman L, Taavitsainen P, Pelkonen O, Bertilsson L. CYP2D6 polymorphism is not crucial for the disposition of selegiline. 1998;64:402-11
Scheuerer S, Hall SD, Williams KM, Geisslinger G. Effect of clofibrate on the chiral inversion of ibuprofen in healthy volunteers. 1998;64:168-76
Schmader KE (see Hanlon et al). 1998;64:684-92
Schmetterer L (see Dorner et al). 1998;64:322-30
Schmidt A-G (see Kovarik et al). 1998;64:66-72
Schnider TW (see Gambús et al). 1998;64:27-38
Schnyder C (see Eap et al). 1998;64:52-7
Schoemaker RC (see van Haarst et al). 1998;64:542-6
Selenko N (see Dorner et al). 1998;64:322-30
Sellers EM (see Nowak et al). 1998;64:378-83
Sentrakul P (see Chompootawee et al). 1998;64:204-10
Sethna NF (see Dionne et al). 1998;64:562-8
Seto WH (see Kumana et al). 1998;64:569-74
Shader RI (see Greenblatt et al). 1998;64:237-47
Shader RI (see Greenblatt et al). 1998;64:278-85
Shader RI (see Greenblatt et al). 1998;64:553-61
Shader RI (see Greenblatt et al). 1998;64:661-71
Shafer SL (see Angst et al). 1998;64:499-51
Shafer SL (see Gambús et al). 1998;64:27-38
Siproudhis L, Bellissant E, Juguet F, Allain H, Bretagne JF, Gosselin M. Octreotide acts on anorectal physiology: a dynamic study in healthy subjects. 1998;64:424-32
Sjöqvist F (see Yue et al). 1998;64:384-90
Slattery JT (see Ren et al). 1998;64:289-301
Smith DE. CYP3A4 and the erythromycin breath test. 1998;64:130 (Letter reply)
Squifflet JP (see Hale et al). 1998;64:672-83
Steiner E (see von Bahr et al). 1998;64:18-26
Stepanians M (see D'Agostino et al). 1998;64:579-96 (Commentary)
Stevens R (see Piscitelli et al). 1998;64:492-8
Stoltz M (see Russell et al). 1998;64:612-21
Svensson USH, Ashton M, Hai TN, Bertilsson L, Huang DX, Van Huang N, Niño NT, Sy ND, Lykkesfeldt J, Công LD. Artemisinin induced omeprazole metabolism in human beings. 1998;64:160-7
Swartzman LC, Burkell J. Expectations and the placebo effect in clinical drug trials: why we should not turn a blind eye to unblinding, and other cautionary notes. 1998;64:1-7 (Commentary)
Sy ND (see Svensson et al). 1998;64:160-7

T

Taavitsainen P (see Scheinin et al). 1998;64:402-11
Tammara VK (see Mahmood et al). 1998;64:547-52
Thacker D (see Trapnell et al). 1998;64:597-602
Thummel KE (see Kharasch et al). 1998;64:39-45
Tobias S (see Greenblatt et al). 1998;64:237-47
Topouchian J (see Lafleche et al). 1998;64:96-105
Toublanc N (see Hempel et al). 1998;64:622-35
Trapnell CB, Donahue SR, Collins JM, Flockhart DA, Thacker D, Abernethy DR. Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone. 1998;64:597-602
Trivijitsilp P (see Chompootawee et al). 1998;64:204-10
Trocóniz IF, Naukkarinen TH, Ruottinen HM, Rinne UK, Gordin A, Karlsson MO. Population pharmacodynamic modeling of levodopa in patients with Parkinson's disease receiving entacapone. 1998;64:106-16
Tybring G (see Herrlin et al). 1998;64:391-401
Tybring G (see Yue et al). 1998;64:384-90
Tyndale RF (see Nowak et al). 1998;64:378-83

V

- van der Dijks B (*see* Lechin *et al.*). 1998;64:223-32
Van de Woude FJ (*see* Hale *et al.*). 1998;64:672-83
van Gerven JMA (*see* van Haarst *et al.*). 1998;64:542-6
van Haarst AD, van't Klooster GAE, van Gerven JMA, Schoemaker RC, van Oene JC, Burggraaf J, Coene MC, Cohen AF. The influence of cisapride and clarithromycin on QT intervals in healthy volunteers. 1998;64:542-6
Van Huong N (*see* Svensson *et al.*). 1998;64:160-7
van Oene JC (*see* van Haarst *et al.*). 1998;64:542-6
Vanrenterghem Y (*see* Hale *et al.*). 1998;64:672-83
van't Klooster GAE (*see* van Haarst *et al.*). 1998;64:542-6
Varis T, Kaukonen KM, Kivistö KT, Neuvonen PJ. Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. 1998;64:363-8
Verpooten GA (*see* Hale *et al.*). 1998;64:672-83
Vestal RE. The clinical pharmacologist: An endangered species? 1998;64:471-6 (Commentary)
Villikka K (*see* Kivistö *et al.*). 1998;64:648-54
Vogel S (*see* Piscitelli *et al.*). 1998;64:492-8
von Bahr C, Steiner E, Koike Y, Gabrielsson J. Time course of enzyme induction in humans: effect of pentobarbital on nortriptyline metabolism. 1998;64:18-26
von Moltke LL (*see* Greenblatt *et al.*). 1998;64:237-47
von Moltke LL (*see* Greenblatt *et al.*). 1998;64:278-85
von Moltke LL (*see* Greenblatt *et al.*). 1998;64:553-61
von Moltke LL (*see* Greenblatt *et al.*). 1998;64:661-71

W

- Wacholtz MC (*see* Cheung *et al.*). 1998;64:412-23
Wagner D. CYP3A4 and the erythromycin breath test. 1998;64:129 (Letter)
Wakasugi H, Yano I, Ito T, Hashida T, Futami T, Nohara R, Sasayama S, Inui K-i. Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein. 1998;64:123-8
Wall WE Jr (*see* Hanlon *et al.*). 1998;64:684-92
Wallis EJ, Ramsay LE, Hettiarachchi J. Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension. 1998;64:439-49
Weimar W (*see* Hale *et al.*). 1998;64:672-83
Weinshilboum RM. A message from the Finance Committee Chairperson. 1998;64:467

- Weintraub M (*see* D'Agostino *et al.*). 1998;64:579-96 (Commentary)
Weir S (*see* Russell *et al.*). 1998;64:612-21
Wennerholm A (*see* Herrlin *et al.*). 1998;64:391-401
Wilkinson GR (*see* Adedoyin *et al.*). 1998;64:8-17
Williams KM (*see* Scheuerer *et al.*). 1998;64:168-76
Wilmet CS (*see* Lafleche *et al.*). 1998;64:96-105
Wolzt M (*see* Dörner *et al.*). 1998;64:322-30
Woosley RL (*see* Abernethy and Woosley). 1998;64:694
Woosley RL (*see* Yasuda *et al.*). 1998;64:536-41
Wright CE (*see* Greenblatt *et al.*). 1998;64:237-47
Wright CE (*see* Greenblatt *et al.*). 1998;64:278-85

X

- Xie HG. How to correctly calculate the proportions of the heterozygotes and homozygotes in the extensive metabolizers of a certain drug-metabolizing enzyme in an ethnic or racial population? 1998;64:575 (Letter)

Y

- Yano I (*see* Wakasugi *et al.*). 1998;64:123-8
Yasuda SU, Nagashima S, Douyon E, Benton RE, Woosley RL, Barbey JT. Adenosine A₁-receptor occupancy predicts A₁-receptor antagonist effects of N-0861. 1998;64:536-41
Yates CR (*see* Loennechen *et al.*). 1998;64:46-51
Yeretzian J (*see* Major *et al.*). 1998;64:450-61
Younes F (*see* Major *et al.*). 1998;64:450-61
Youngs EJ (*see* Gambús *et al.*). 1998;64:27-38
Yu AS (*see* Bowen *et al.*). 1998;64:339-46
Yue QY, Zhong ZH, Tybring G, Dalén P, Dahl ML, Bertilsson L, Sjöqvist F. Pharmacokinetics of nortriptyline and its 10-hydroxy-metabolite in Chinese subjects of different CYP2D6 genotypes. 1998;64:384-90

Z

- Zevin S, Jacob P III, Benowitz NL. Dose-related cardiovascular and endocrine effects of transdermal nicotine. 1998;64:87-95
Zhong ZH (*see* Yue *et al.*). 1998;64:384-90
Zieleniuk I (*see* Rosenzweig *et al.*). 1998;64:211-22
Zylber-Katz E (*see* Levy *et al.*). 1998;64:117-22

Subject index

A

Abacavir sulfate

Abacavir sulfate (USAN List No. 407). 1998;64:236

Abarelix

Abarelix (USAN List No. 407). 1998;64:235

Adenosine

Adenosine A_1 -receptor occupancy predicts A_1 -receptor antagonist effects of N-0861 (Yasuda et al). 1998;64:536-41

Administration, vaginal

The use of two estrogen preparations (a combined contraceptive pill versus conjugated estrogen cream) intravaginally to treat urogenital symptoms in postmenopausal Thai women: a comparative study (Chompootaweep et al). 1998;64:204-10

Adrenergic beta receptor blockers

Catecholamines and heart function in heart transplant patients: effects of β_1 - versus nonselective β -blockade (Leenen et al). 1998;64:522-35

Aged

Benzodiazepine use and cognitive function among community-dwelling elderly (Hanlon et al). 1998;64:684-92

Cognitive performance in elderly subjects after a single dose of bexloxtone, a new reversible selective monoamine oxidase A inhibitor (Rosenzweig et al). 1998;64:211-22

Alcoholism

Inhibition of CYP2E1 by chlormethiazole as measured by chlorzoxazone pharmacokinetics in patients with alcoholism and in healthy volunteers (Eap et al). 1998;64:52-7

Alleles

Canadian Native Indians exhibit unique *CYP2A6* and *CYP2C19* mutant allele frequencies (Nowak et al). 1998;64:378-83

Pharmacokinetics of nortriptyline and its 10-hydroxymetabolite in Chinese subjects of different *CYP2D6* genotypes (Yue et al). 1998;64:384-90

Allergy; see Hypersensitivity

Alprazolam

Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences (Greenblatt et al). 1998;64:237-47

American Society for Clinical Pharmacology and Therapeutics

Future meeting dates and sites of the ASCPT. 1998;64:105, 149

A message from the Finance Committee Chairperson (Weinshilboum). 1998;64:467

A message from the President: the Centennial ASCPT meeting—come to San Antonio, March 18-20, 1999 (Peck). 1998;64:693-4

1999 ASCPT Clinical Pharmacology Curriculum Review Course (Abernethy and Woosley). 1998;64:694

Nominations for awards. 1998;64:349-50

Amiodarone

Amiodarone causes endothelium-dependent vasodilation in human hand veins in vivo (Grossmann et al). 1998;64:302-11

Anemia, sickle cell

Nomegestrol acetate contraceptive implant use by women with sickle cell disease (de Lourdes Pires Nascimento et al). 1998;64:433-8

Angiotensin-converting enzyme

Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension (Wallis et al). 1998;64:439-49

Antibiotics

Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences (Greenblatt et al). 1998;64:278-85

Antibodies, monoclonal

Phase I study of a humanized anti-CD11/CD18 monoclonal antibody in multiple sclerosis (Bowen et al). 1998;64:339-46

Anticonvulsants

Does percent reduction in seizure frequency correlate with plasma concentration of anticonvulsant drugs? experience with four anticonvulsant drugs (Mahmood et al). 1998;64:547-52

Antidepressive agents

Neuropharmacologic treatment of bronchial asthma with the antidepressant tianeptine: a double-blind, crossover placebo-controlled study (Lechin et al). 1998;64:223-32

Antihistaminics

The effectiveness of antihistamines in reducing the severity of runny nose and sneezing: a meta-analysis (D'Agostino et al). 1998;64:579-96 (Commentary)

Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers (Russell et al). 1998;64:612-21

Antineoplastic agents

Indirect-response model for the time course of leukopenia with anticancer drugs (Minami et al). 1998;64:511-21

Antilucer agents

Antilucer drug prescribing in hospital successfully influenced by "immediate concurrent feedback" (Kumana et al). 1998;64:569-74

Anus

Octreotide acts on anorectal physiology: a dynamic study in healthy subjects (Siproudhis et al). 1998;64:424-32

Apafant

Apafant (USAN List No. 407). 1998;64:236

Arofylline

Arofylline (USAN List No. 407). 1998;64:234

Artemisinin

Artemisinin induced omeprazole metabolism in human beings (Svensson et al). 1998;64:160-7

Asthma

Neuropharmacologic treatment of bronchial asthma with the antidepressant tianeptine: a double-blind, crossover placebo-controlled study (Lechin et al). 1998;64:223-32

Atorvastatin

Effect of itraconazole on the pharmacokinetics of atorvastatin (Kantola et al). 1998;64:58-65

Atreleuton

Atreleuton (USAN List No. 407). 1998;64:236

July, pp. 1-132; August, pp. 133-236; September, pp. 237-352; October, pp. 353-470; November, pp. 471-578; December, pp. 579-714. Index to the ASCPT meeting abstracts is located in the February issue.

B

Bantu Tanzania; see Tanzania**Basiliximab**

Disposition and immunodynamics of basiliximab in liver allograft recipients (Kovarik et al). 1998;64:66-72

Befloxatone

Cognitive performance in elderly subjects after a single dose of befloxtatone, a new reversible selective monoamine oxidase A inhibitor (Rosenzweig et al). 1998;64:211-22

Benzodiazepines

Benzodiazepine use and cognitive function among community-dwelling elderly (Hanlon et al). 1998;64:684-92

Bibapitide

Bibapitide (USAN List No. 408). 1998;64:352

Blood pressure

Differential responses of the heart and vasculature to chronic blood pressure reduction in essential hypertension (Lafleche et al). 1998;64:96-105

Population pharmacokinetic-pharmacodynamic modeling of moxonidine with 24-hour ambulatory blood pressure measurements (Hempel et al). 1998;64:622-35

Blood vessels

Differential responses of the heart and vasculature to chronic blood pressure reduction in essential hypertension (Lafleche et al). 1998;64:96-105

Dose-related cardiovascular and endocrine effects of transdermal nicotine (Zevin et al). 1998;64:87-95

Bone marrow transplantation

Pharmacokinetics of cyclophosphamide and its metabolites in bone marrow transplantation patients (Ren et al). 1998;64:289-301

Bupirone

Bupirone plasma concentrations (Barbanj et al) (Letter); (Kivistö et al) (Reply). 1998;64:347-8

Grapefruit juice substantially increases plasma concentrations of bupirone (Lilja et al). 1998;64:655-60

C

Caffeine

Caffeine in tension headache (Migliardi et al). 1998;64:465-6 (Letter)

Canada

Canadian Native Indians exhibit unique *CYP2A6* and *CYP2C19* mutant allele frequencies (Nowak et al). 1998;64:378-83

Carbamazepine

Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy (Garg et al). 1998;64:286-8

Catecholamines

Catecholamines and heart function in heart transplant patients: effects of β_1 - versus nonselective β -blockade (Leenen et al). 1998;64:522-35

CD11/CD18; see Integrins**Cerebrospinal fluid**

Cerebrospinal fluid prostaglandins after systemic dipyron intake (Levy et al). 1998;64:117-22

China

Pharmacokinetics of nortriptyline and its 10-hydroxymetabolite in Chinese subjects of different *CYP2D6* genotypes (Yue et al). 1998;64:384-90

Chlormethiazole

Inhibition of CYP2E1 by chlormethiazole as measured by chlorzoxazone pharmacokinetics in patients with alcoholism and in healthy volunteers (Eap et al). 1998;64:52-7

Chlorzoxazone

Inhibition of chlorzoxazone metabolism, a clinical probe for CYP2E1, by a single ingestion of watercress (Leclercq et al). 1998;64:144-9

Inhibition of CYP2E1 by chlormethiazole as measured by chlorzoxazone pharmacokinetics in patients with alcoholism and in healthy volunteers (Eap et al). 1998;64:52-7

Cisapride

The influence of cisapride and clarithromycin on QT intervals in healthy volunteers (van Haarst et al). 1998;64:542-6

Clarithromycin

The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin (Gorski et al). 1998;64:133-43

Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein (Wakasugi et al). 1998;64:123-8

The influence of cisapride and clarithromycin on QT intervals in healthy volunteers (van Haarst et al). 1998;64:542-6

Pharmacokinetic interaction between ritonavir and clarithromycin (Ouellet et al). 1998;64:355-62

Clinical pharmacology

The clinical pharmacologist: An endangered species? (Vestal). 1998;64:471-6 (Commentary)

1999 ASCPT Clinical Pharmacology Curriculum Review Course (Abernethy and Woosley). 1998;64:694

Clinical trials

Expectations and the placebo effect in clinical drug trials: why we should not turn a blind eye to unblinding, and other cautionary notes (Swartzman and Burkell). 1998;64:1-7 (Commentary)

Clofibrate

Effect of clofibrate on the chiral inversion of ibuprofen in healthy volunteers (Scheuerer et al). 1998;64:168-76

Coenzyme A

Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors (Lilja et al). 1998;64:477-83

Cognition

Benzodiazepine use and cognitive function among community-dwelling elderly (Hanlon et al). 1998;64:684-92

Cognitive performance in elderly subjects after a single dose of befloxtatone, a new reversible selective monoamine oxidase A inhibitor (Rosenzweig et al). 1998;64:211-22

Commentaries

Commentaries. 1998;64:1-7, 353-4, 471-6, 579-96

Common cold

The effectiveness of antihistamines in reducing the severity of runny nose and sneezing: a meta-analysis (D'Agostino et al). 1998;64:579-96 (Commentary)

Contraceptives

Nomegestrol acetate contraceptive implant use by women with sickle cell disease (de Lourdes Pires Nascimento et al). 1998;64:433-8

Contraceptives, oral

The use of two estrogen preparations (a combined contraceptive pill versus conjugated estrogen cream) intravaginally to treat urogenital symptoms in postmenopausal Thai women: a comparative study (Chompootaweep et al). 1998;64:204-10

Corticotropin-releasing factor

Pharmacokinetics, cortisol release, and hemodynamics after intravenous and subcutaneous injection of human corticotropin-releasing factor in humans (Angst et al). 1998;64:499-51

Cortisol

Pharmacokinetics, cortisol release, and hemodynamics after intravenous and subcutaneous injection of human corticotropin-releasing factor in humans (Angst et al). 1998;64:499-51

CP-99,994

The substance P receptor antagonist CP-99,994 reduces acute post-operative pain (Dionne et al). 1998;64:562-8

Cyclophosphamide

Pharmacokinetics of cyclophosphamide and its metabolites in bone marrow transplantation patients (Ren et al). 1998;64:289-301

Cytochrome P450

Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their *CYP2C19* genotype (Hertlin et al). 1998;64:391-401

Canadian Native Indians exhibit unique *CYP2A6* and *CYP2C19* mutant allele frequencies (Nowak et al). 1998;64:378-83

The contribution of intestinal and hepatic *CYP3A* to the interaction between midazolam and clarithromycin (Gorski et al). 1998;64:133-43

CYP2D6 polymorphism is not crucial for the disposition of selegiline (Scheinin et al). 1998;64:402-11

Effect of fluvoxamine therapy on the activities of *CYP1A2*, *CYP2D6*, and *CYP3A* as determined by phenotyping (Kashuba et al). 1998;64:257-68

Effects of blocking *CYP2D6* on the pharmacokinetics and pharmacodynamics of oxycodone (Heiskanen et al). 1998;64:603-11

Inhibition of chlorzoxazone metabolism, a clinical probe for *CYP2E1*, by a single ingestion of watercress (Leclercq et al). 1998;64:144-9

Inhibition of *CYP2E1* by chlormethiazole as measured by chlorzoxazone pharmacokinetics in patients with alcoholism and in healthy volunteers (Eap et al). 1998;64:52-7

Metabolism of ropivacaine in humans is mediated by *CYP1A2* and to a minor extent by *CYP3A4*: an interaction study with fluvoxamine and ketoconazole as in vivo inhibitors (Arlander et al). 1998;64:484-9

Pharmacokinetics of nortriptyline and its 10-hydroxymetabolite in Chinese subjects of different *CYP2D6* genotypes (Yue et al). 1998;64:384-90

Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on *CYP3A* activity as measured by phenotyping with intravenous midazolam (Kashuba et al). 1998;64:269-77

Selective effect of liver disease on the activities of specific metabolizing enzymes: investigation of cytochromes P450 2C19 and 2D6 (Adedoyin et al). 1998;64:8-17

Single-dose disulfiram does not inhibit *CYP2A6* activity (Kharasch et al). 1998;64:39-45

D

Denileukin diftitox

Denileukin diftitox (USAN List No. 406). 1998;64:131

Digoxin

Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein (Wakasugi et al). 1998;64:123-8

Dihydrotestosterone

A model for the turnover of dihydrotestosterone in the presence of the irreversible 5 α -reductase inhibitors G1198745 and finasteride (Olsson Gisleskog et al). 1998;64:636-47

Dihydroxybergamottin

Grapefruit juice-felodipine interaction: effect of naringin and 6',7'-dihydroxybergamottin in humans (Bailey et al). 1998;64:248-56

Diltiazem

The interaction of diltiazem with lovastatin and pravastatin (Azie et al). 1998;64:369-77

Dipyrone

Cerebrospinal fluid prostaglandins after systemic dipyrone intake (Levy et al). 1998;64:117-22

Disulfiram

Single-dose disulfiram does not inhibit *CYP2A6* activity (Kharasch et al). 1998;64:39-45

DNA

Isolation of a human thiopurine S-methyltransferase (TPMT) complementary DNA with a single nucleotide transition A719G (*TPMT*3C*) and its association with loss of TPMT protein and catalytic activity in humans (Loennechen et al). 1998;64:46-51

Dofetilide

Dynamic analysis of dofetilide-induced changes in ventricular repolarization (Lande et al). 1998;64:312-21

Drug clearance

Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences (Greenblatt et al). 1998;64:278-85

Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences (Greenblatt et al). 1998;64:237-47

Drug development

Drugs and the liver (Reidenberg and Breckenridge). 1998;64:353-4 (Commentary)

Drugs in liver disease (Branch) (Letter); (Reidenberg) (Reply). 1998;64:462-5

Drug dosing

Dose-related cardiovascular and endocrine effects of transdermal nicotine (Zevin et al). 1998;64:87-95

Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers (Russell et al). 1998;64:612-21

Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects (Cheung et al). 1998;64:412-23

Drug implants

Nomegestrol acetate contraceptive implant use by women with sickle cell disease (de Lourdes Pires Nascimento et al). 1998;64:433-8

Drug interactions

Buspirone plasma concentrations (Barbanoj et al) (Letter); (Kivistö et al) (Reply). 1998;64:347-8

The contribution of intestinal and hepatic *CYP3A* to the interaction between midazolam and clarithromycin (Gorski et al). 1998;64:133-43

Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein (Wakasugi et al). 1998;64:123-8

Effect of clofibrate on the chiral inversion of ibuprofen in healthy volunteers (Scheuerer et al). 1998;64:168-76

Effect of itraconazole on the pharmacokinetics of atorvastatin (Kantola et al). 1998;64:58-65

- Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations (Kantola et al). 1998; 64:177-82
- Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences (Greenblatt et al). 1998;64:278-85
- Interaction between warfarin and 5-fluorouracil, not between warfarin and levamisole (Brown). 1998;64:233 (Letter)
- The interaction of diltiazem with lovastatin and pravastatin (Azie et al). 1998;64:369-77
- Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences (Greenblatt et al). 1998;64:237-47
- Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole (Greenblatt et al). 1998;64:661-71
- Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: an interaction study with fluvoxamine and ketoconazole as in vivo inhibitors (Arlander et al). 1998;64:484-9
- Pharmacokinetic interaction between ritonavir and clarithromycin (Ouellet et al). 1998;64:355-62
- Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole (Varis et al). 1998;64:363-8
- Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin (Kivistö et al). 1998;64:648-54
- Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone (Trapnell et al). 1998;64:597-602
- Drug metabolism**
- Artemisinin induced omeprazole metabolism in human beings (Svensson et al). 1998;64:160-7
- How to correctly calculate the proportions of the heterozygotes and homozygotes in the extensive metabolizers of a certain drug-metabolizing enzyme in an ethnic or racial population? (Xie) (Letter); (Kohli) (Reply). 1998;64:575
- Inhibition of chlorzoxazone metabolism, a clinical probe for CYP2E1, by a single ingestion of watercress (Leclercq et al). 1998;64:144-9
- Metabolism and action of uroclatin infusion in healthy volunteers (Carstens et al). 1998;64:73-86
- Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: an interaction study with fluvoxamine and ketoconazole as in vivo inhibitors (Arlander et al). 1998;64:484-9
- Selective effect of liver disease on the activities of specific metabolizing enzymes: investigation of cytochromes P450 2C19 and 2D6 (Adedoyin et al). 1998;64:8-17
- Selective effects of somatostatin analogs on human drug-metabolizing enzymes (Rasmussen et al). 1998;64:150-9
- Time course of enzyme induction in humans: effect of pentobarbital on nortriptyline metabolism (von Bahr et al). 1998;64:18-26
- Drug trials**
- Expectations and the placebo effect in clinical drug trials: why we should not turn a blind eye to unblinding, and other cautionary notes (Swartzman and Burkell). 1998;64:1-7 (Commentary)
- Dynorphin**
- Pharmacokinetics of intravenous dynorphin A(1-13) in opioid-naïve and opioid-treated human volunteers (Gambús et al). 1998;64:27-38
- E**
- Elderly; see Aged**
- Electrocardiography**
- Dynamic analysis of dofetilide-induced changes in ventricular repolarization (Lande et al). 1998;64:312-21
- The influence of cisapride and clarithromycin on QT intervals in healthy volunteers (van Haarst et al). 1998;64:542-6
- Endocrine system**
- Dose-related cardiovascular and endocrine effects of transdermal nicotine (Zevin et al). 1998;64:87-95
- Endothelium, vascular**
- Amiodarone causes endothelium-dependent vasodilation in human hand veins in vivo (Grossmann et al). 1998;64:302-11
- Entacapone**
- Entacapone (USAN List No. 408). 1998;64:351
- Population pharmacodynamic modeling of levodopa in patients with Parkinson's disease receiving entacapone (Trocóniz et al). 1998; 64:106-16
- Enzymes**
- Selective effects of somatostatin analogs on human drug-metabolizing enzymes (Rasmussen et al). 1998;64:150-9
- Time course of enzyme induction in humans: effect of pentobarbital on nortriptyline metabolism (von Bahr et al). 1998;64:18-26
- Epilepsy**
- Does percent reduction in seizure frequency correlate with plasma concentration of anticonvulsant drugs? experience with four anticonvulsant drugs (Mahmood et al). 1998;64:547-52
- Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy (Garg et al). 1998;64:286-8
- Erythromycin**
- Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations (Kantola et al). 1998; 64:177-82
- Erythropoietin**
- Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects (Cheung et al). 1998;64:412-23
- Essential hypertension; see Hypertension**
- Estrogen**
- The use of two estrogen preparations (a combined contraceptive pill versus conjugated estrogen cream) intravaginally to treat urogenital symptoms in postmenopausal Thai women: a comparative study (Chompootawee et al). 1998;64:204-10
- Ethinyl estradiol**
- Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone (Trapnell et al). 1998;64:597-602
- Ethnic factors**
- How to correctly calculate the proportions of the heterozygotes and homozygotes in the extensive metabolizers of a certain drug-metabolizing enzyme in an ethnic or racial population? (Xie) (Letter); (Kohli) (Reply). 1998;64:575
- F**
- Felodipine**
- Grapefruit juice-felodipine interaction: effect of naringin and 6',7'-dihydroxybergamottin in humans (Bailey et al). 1998;64:248-56
- Fexofenadine**
- Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers (Russell et al). 1998;64:612-21

Finasteride

A model for the turnover of dihydrotestosterone in the presence of the irreversible 5 α -reductase inhibitors GI198745 and finasteride (Olsson Gisleskog et al). 1998;64:636-47

Fluconazole

Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole (Greenblatt et al). 1998;64:661-71

Fluorouracil

Interaction between warfarin and 5-fluorouracil, not between warfarin and levamisole (Brown). 1998;64:233 (Letter)

Fluvoxamine

Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping (Kashuba et al). 1998;64:257-68

Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: an interaction study with fluvoxamine and ketoconazole as *in vivo* inhibitors (Arlander et al). 1998;64:484-9

Food-drug interactions

Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy (Garg et al). 1998;64:286-8

Grapefruit juice substantially increases plasma concentrations of buspirone (Lilja et al). 1998;64:655-60

Grapefruit juice-felodipine interaction: effect of naringin and 6',7'-dihydroxybergamottin in humans (Bailey et al). 1998;64:248-56

Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors (Lilja et al). 1998;64:477-83

Inhibition of chlorzoxazone metabolism, a clinical probe for CYP2E1, by a single ingestion of watercress (Leclercq et al). 1998;64:144-9

Formoterol/fumarate

Formoterol/fumarate (USAN List No. 409). 1998;64:469

G

Gatifloxacin

Gatifloxacin (USAN List No. 409). 1998;64:468

Gender factors

Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam (Kashuba et al). 1998;64:269-77

Genotype

Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their *CYP2C19* genotype (Herrlin et al). 1998;64:391-401

Pharmacokinetics of nortriptyline and its 10-hydroxymetabolite in Chinese subjects of different *CYP2D6* genotypes (Yue et al). 1998;64:384-90

GI198745

A model for the turnover of dihydrotestosterone in the presence of the irreversible 5 α -reductase inhibitors GI198745 and finasteride (Olsson Gisleskog et al). 1998;64:636-47

Glycoproteins

Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein (Wakasugi et al). 1998;64:123-8

Grapefruit juice

Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy (Garg et al). 1998;64:286-8

Grapefruit juice substantially increases plasma concentrations of buspirone (Lilja et al). 1998;64:655-60

Grapefruit juice-felodipine interaction: effect of naringin and 6',7'-dihydroxybergamottin in humans (Bailey et al). 1998;64:248-56

Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors (Lilja et al). 1998;64:477-83

Guest reviewers

Guest reviewers. 1998;64:470

H

Hand

Amiodarone causes endothelium-dependent vasodilation in human hand veins *in vivo* (Grossmann et al). 1998;64:302-11

Headache

Caffeine in tension headache (Migliardi et al). 1998;64:465-6 (Letter)

Heart

Differential responses of the heart and vasculature to chronic blood pressure reduction in essential hypertension (Lafleche et al). 1998;64:96-105

Dose-related cardiovascular and endocrine effects of transdermal nicotine (Zevin et al). 1998;64:87-95

Heart rate

Dynamic analysis of dofetilide-induced changes in ventricular repolarization (Lande et al). 1998;64:312-21

Pharmacokinetic-pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers (Ragueneau et al). 1998;64:192-203

Heart transplantation

Catecholamines and heart function in heart transplant patients: effects of β_1 - versus nonselective β -blockade (Leenen et al). 1998;64:522-35

Hemodynamics

Catecholamines and heart function in heart transplant patients: effects of β_1 - versus nonselective β -blockade (Leenen et al). 1998;64:522-35

Hemodynamic effects of continuous urotilatin infusion: a dose-finding study (Dorner et al). 1998;64:322-30

Pharmacokinetics, cortisol release, and hemodynamics after intravenous and subcutaneous injection of human corticotropin-releasing factor in humans (Angst et al). 1998;64:499-51

Heterozygotes

How to correctly calculate the proportions of the heterozygotes and homozygotes in the extensive metabolizers of a certain drug-metabolizing enzyme in an ethnic or racial population? (Xie) (Letter); (Kohli) (Reply). 1998;64:575

HIV

Concentration-controlled zidovudine therapy (Fletcher et al). 1998;64:331-8

Pharmacokinetic modeling of recombinant interleukin-2 in patients with human immunodeficiency virus infection (Piscitelli et al). 1998;64:492-8

Homozygotes

How to correctly calculate the proportions of the heterozygotes and homozygotes in the extensive metabolizers of a certain drug-metabolizing enzyme in an ethnic or racial population? (Xie) (Letter); (Kohli) (Reply). 1998;64:575

Hospitalization

Drug-related hospitalization at a tertiary teaching center in Lebanon: incidence, associations, and relation to self-medicating behavior (Major et al). 1998;64:450-61

3-Hydroxy-3-methylglutaryl

Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors (Lilja et al). 1998;64:477-83

Hypersensitivity

Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers (Russell et al). 1998;64:612-21

Hypertension

Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension (Wallis et al). 1998;64:439-49

Differential responses of the heart and vasculature to chronic blood pressure reduction in essential hypertension (Lafleche et al). 1998;64:96-105

I**Ibandronate sodium**

Ibandronate sodium (USAN List No. 408). 1998;64:351

Ibuprofen

Effect of clofibrate on the chiral inversion of ibuprofen in healthy volunteers (Scheuerer et al). 1998;64:168-76

Immediate concurrent feedback

Antulcer drug prescribing in hospital successfully influenced by "immediate concurrent feedback" (Kumana et al). 1998;64:569-74

Indians

Canadian Native Indians exhibit unique *CYP2A6* and *CYP2C19* mutant allele frequencies (Nowak et al). 1998;64:378-83

Integrins

Phase I study of a humanized anti-CD11/CD18 monoclonal antibody in multiple sclerosis (Bowen et al). 1998;64:339-46

Interleukin-2

Pharmacokinetic modeling of recombinant interleukin-2 in patients with human immunodeficiency virus infection (Piscitelli et al). 1998;64:492-8

Intestines

The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin (Gorski et al). 1998;64:133-43

Intravaginal administration; see Administration, vaginal**Itraconazole**

Effect of itraconazole on the pharmacokinetics of atorvastatin (Kantola et al). 1998;64:58-65

Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole (Greenblatt et al). 1998;64:661-71

Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole (Varis et al). 1998;64:363-8

Ivabradine

Pharmacokinetic-pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers (Ragueneau et al). 1998;64:192-203

K**Ketoconazole**

Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences (Greenblatt et al). 1998;64:237-47

Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole (Greenblatt et al). 1998;64:661-71

Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: an interaction study with fluvoxamine and ketoconazole as *in vivo* inhibitors (Arlander et al). 1998;64:484-9

Kidney

Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein (Wakasugi et al). 1998;64:123-8

Hemodynamic effects of continuous urodelatin infusion: a dose-finding study (Dorner et al). 1998;64:322-30

Kidney transplantation

The pharmacokinetic/pharmacodynamic relationship for mycophenolate mofetil in renal transplantation (Hale et al). 1998;64:672-83

L**Lebanon**

Drug-related hospitalization at a tertiary teaching center in Lebanon: incidence, associations, and relation to self-medicating behavior (Major et al). 1998;64:450-61

Ledoxantrone trihydrochloride

Ledoxantrone trihydrochloride (USAN List No. 409). 1998;64:469

Lenercept

Lenercept (USAN List No. 407). 1998;64:234

Letters

Buspirone plasma concentrations (Barbanoj et al) (Letter); (Kivistö et al) (Reply). 1998;64:347-8

Caffeine in tension headache (Migliardi et al). 1998;64:465-6

CYP3A4 and the erythromycin breath test (Wagner) (Letter); (Smith) (Reply). 1998;64:129-30

Drugs in liver disease (Branch) (Letter); (Reidenberg) (Reply). 1998;64:462-5

How to correctly calculate the proportions of the heterozygotes and homozygotes in the extensive metabolizers of a certain drug-metabolizing enzyme in an ethnic or racial population? (Xie) (Letter); (Kohli) (Reply). 1998;64:575

Interaction between warfarin and 5-fluorouracil, not between warfarin and levamisole (Brown). 1998;64:233

Leukopenia

Indirect-response model for the time course of leukopenia with anticancer drugs (Minami et al). 1998;64:511-21

Levalbuterol sulfate

Levalbuterol sulfate (USAN List No. 411). 1998;64:695

Levalbuterol hydrochloride

Levalbuterol hydrochloride (USAN List No. 409). 1998;64:468

Levamisole

Interaction between warfarin and 5-fluorouracil, not between warfarin and levamisole (Brown). 1998;64:233 (Letter)

Levodopa

Concentration-response relationship of levodopa in patients at different stages of Parkinson's disease (Harder and Baas). 1998;64:183-91

Population pharmacodynamic modeling of levodopa in patients with Parkinson's disease receiving entacapone (Trocóniz et al). 1998;64:106-16

Liver

The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin (Gorski et al). 1998;64:133-43

Liver disease

Drugs and the liver (Reidenberg and Breckenridge). 1998;64:353-4 (Commentary)

Drugs in liver disease (Branch) (Letter); (Reidenberg) (Reply). 1998;64:462-5

Selective effect of liver disease on the activities of specific metabolizing enzymes: investigation of cytochromes P450 2C19 and 2D6 (Adedoyin et al). 1998;64:8-17

Liver transplantation

Disposition and immunodynamics of basiliximab in liver allograft recipients (Kovarik et al). 1998;64:66-72

Lotrafiban hydrochloride

Lotrafiban hydrochloride (USAN List No. 411). 1998;64:696

Lovastatin

The interaction of diltiazem with lovastatin and pravastatin (Aziz et al). 1998;64:369-77

M

Macrolide antimicrobials; see Antibiotics

Meloxicam

Meloxicam (USAN List No. 410). 1998;64:576

Menstruation

Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam (Kashuba et al). 1998;64:269-77

Mephenytoin

Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype (Herrlin et al). 1998;64:391-401

Mespiperone C 11

Mespiperone C 11 (USAN List No. 411). 1998;64:695

Methylprednisolone

Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole (Varis et al). 1998;64:363-8

Midazolam

The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin (Gorski et al). 1998;64:133-43

Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam (Kashuba et al). 1998;64:269-77

Monoamine oxidase inhibitors

Cognitive performance in elderly subjects after a single dose of befloraxone, a new reversible selective monoamine oxidase A inhibitor (Rosenzweig et al). 1998;64:211-22

Monoclonal antibodies; see Antibodies, monoclonal

Moxonidine

Population pharmacokinetic-pharmacodynamic modeling of moxonidine with 24-hour ambulatory blood pressure measurements (Hempel et al). 1998;64:622-35

Multiple sclerosis

Phase I study of a humanized anti-CD11/CD18 monoclonal antibody in multiple sclerosis (Bowen et al). 1998;64:339-46

Mutation

Canadian Native Indians exhibit unique CYP2A6 and CYP2C19 mutant allele frequencies (Nowak et al). 1998;64:378-83

Mycophenolate mofetil

The pharmacokinetic/pharmacodynamic relationship for mycophenolate mofetil in renal transplantation (Hale et al). 1998;64:672-83

N

N-0861

Adenosine A₁-receptor occupancy predicts A₁-receptor antagonist effects of N-0861 (Yasuda et al). 1998;64:536-41

Narcotics

Pharmacokinetics of intravenous dynorphin A(1-13) in opioid-naïve and opioid-treated human volunteers (Gambús et al). 1998;64:27-38

Naringin

Grapefruit juice-felodipine interaction: effect of naringin and 6',7'-dihydroxybergamottin in humans (Bailey et al). 1998;64:248-56

Nasal congestion

The effectiveness of antihistamines in reducing the severity of runny nose and sneezing: a meta-analysis (D'Agostino et al). 1998;64:579-96 (Commentary)

Nelzarabine

Nelzarabine (USAN List No. 411). 1998;64:696

Neutral endopeptidase

Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension (Wallis et al). 1998;64:439-49

Nicotine

Dose-related cardiovascular and endocrine effects of transdermal nicotine (Zevin et al). 1998;64:87-95

Nomegestrol

Nomegestrol acetate contraceptive implant use by women with sickle cell disease (de Lourdes Pires Nascimento et al). 1998;64:433-8

Norethindrone

Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone (Trapnell et al). 1998;64:597-602

Nortriptyline

Pharmacokinetics of nortriptyline and its 10-hydroxymetabolite in Chinese subjects of different CYP2D6 genotypes (Yue et al). 1998;64:384-90

Time course of enzyme induction in humans: effect of pentobarbital on nortriptyline metabolism (von Bahr et al). 1998;64:18-26

Nucleotides

Isolation of a human thiopurine S-methyltransferase (TPMT) complementary DNA with a single nucleotide transition A719G (TPMT*3C) and its association with loss of TPMT protein and catalytic activity in humans (Loennechen et al). 1998;64:46-51

O

Octreotide

Octreotide acts on anorectal physiology: a dynamic study in healthy subjects (Siproudhis et al). 1998;64:424-32

Omeprazole

Artemisinin induced omeprazole metabolism in human beings (Svensson et al). 1998;64:160-7

Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their *CYP2C19* genotype (Herrlin et al). 1998;64:391-401

Opioids

Pharmacokinetics of intravenous dynorphin A(1-13) in opioid-naïve and opioid-treated human volunteers (Gambús et al). 1998;64:27-38

Oral contraceptives; *see* Contraceptives, oral

Oxycodone

Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone (Heiskanen et al). 1998;64:603-11

P

Pain

The substance P receptor antagonist CP-99,994 reduces acute post-operative pain (Dionne et al). 1998;64:562-8

Palonosetron hydrochloride

Palonosetron hydrochloride (USAN List No. 410). 1998;64:577

Parkinson's disease

Concentration-response relationship of levodopa in patients at different stages of Parkinson's disease (Harder and Baas). 1998;64:183-91

Population pharmacodynamic modeling of levodopa in patients with Parkinson's disease receiving entacapone (Trocóniz et al). 1998;64:106-16

Pentobarbital

Time course of enzyme induction in humans: effect of pentobarbital on nortriptyline metabolism (von Bahr et al). 1998;64:18-26

Pharmacology

The clinical pharmacologist: An endangered species? (Vestal). 1998;64:471-6 (Commentary)

1999 ASCPT Clinical Pharmacology Curriculum Review Course (Abernethy and Woosley). 1998;64:694

Phenotype

Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping (Kashuba et al). 1998;64:257-68

Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam (Kashuba et al). 1998;64:269-77

Placebos

Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo (Greenblatt et al). 1998;64:553-61

Expectations and the placebo effect in clinical drug trials: why we should not turn a blind eye to unblinding, and other cautionary notes (Swartzman and Burkell). 1998;64:1-7 (Commentary)

Neuropharmacologic treatment of bronchial asthma with the antidepressant tianeptine: a double-blind, crossover placebo-controlled study (Lechin et al). 1998;64:223-32

Polymorphism

CYP2D6 polymorphism is not crucial for the disposition of selegiline (Scheinin et al). 1998;64:402-11

Population studies

Population pharmacodynamic modeling of levodopa in patients with Parkinson's disease receiving entacapone (Trocóniz et al). 1998;64:106-16

Population pharmacokinetic-pharmacodynamic modeling of moxonidine with 24-hour ambulatory blood pressure measurements (Hempel et al). 1998;64:622-35

Pramipexole dihydrochloride

Pramipexole dihydrochloride (USAN List No. 410). 1998;64:577

Pravastatin

The interaction of diltiazem with lovastatin and pravastatin (Azie et al). 1998;64:369-77

Prostaglandins

Cerebrospinal fluid prostaglandins after systemic dipyron intake (Levy et al). 1998;64:117-22

Proteins

Isolation of a human thiopurine *S*-methyltransferase (TPMT) complementary DNA with a single nucleotide transition A719G (TPMT*3C) and its association with loss of TPMT protein and catalytic activity in humans (Loennechen et al). 1998;64:46-51

Q

QT interval; *see* Electrocardiography

R

Racial factors

How to correctly calculate the proportions of the heterozygotes and homozygotes in the extensive metabolizers of a certain drug-metabolizing enzyme in an ethnic or racial population? (Xie) (Letter); (Kohli) (Reply). 1998;64:575

Rapacuronium bromide

Rapacuronium bromide (USAN List No. 406). 1998;64:131

Recombinant human erythropoietin; *see* Erythropoietin

Rectum

Octreotide acts on anorectal physiology: a dynamic study in healthy subjects (Siproudhis et al). 1998;64:424-32

Renal transplantation; *see* Kidney transplantation

Retroviruses

Concentration-controlled zidovudine therapy (Fletcher et al). 1998;64:331-8

Rifampin

Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin (Kivistö et al). 1998;64:648-54

Ritonavir

Pharmacokinetic interaction between ritonavir and clarithromycin (Ouellet et al). 1998;64:355-62

Ropivacaine

Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: an interaction study with fluvoxamine and ketoconazole as in vivo inhibitors (Arlander et al). 1998;64:484-9

Rosiglitazone maleate

Rosiglitazone maleate (USAN List No. 411). 1998;64:696

S

Sabcomeline hydrochloride

Sabcomeline hydrochloride (USAN List No. 410). 1998;64:577

Sampatrilat

Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension (Wallis et al). 1998;64:439-49

Seizures

Does percent reduction in seizure frequency correlate with plasma concentration of anticonvulsant drugs? experience with four anticonvulsant drugs (Mahmood et al). 1998;64:547-52

Selegiline

CYP2D6 polymorphism is not crucial for the disposition of selegiline (Scheinin et al). 1998;64:402-11

Self-medication

Drug-related hospitalization at a tertiary teaching center in Lebanon: incidence, associations, and relation to self-medicating behavior (Major et al). 1998;64:450-61

Sex factors; see Gender factors

Sickle cell disease; see Anemia, sickle cell

Simvastatin

Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations (Kantola et al). 1998;64:177-82

Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors (Lilja et al). 1998;64:477-83

Sinus nodes

Pharmacokinetic-pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers (Ragueneau et al). 1998;64:192-203

Sneezing

The effectiveness of antihistamines in reducing the severity of runny nose and sneezing: a meta-analysis (D'Agostino et al). 1998;64:579-96 (Commentary)

Somatostatin

Selective effects of somatostatin analogs on human drug-metabolizing enzymes (Rasmussen et al). 1998;64:150-9

Specialties

The clinical pharmacologist: An endangered species? (Vestal). 1998;64:471-6 (Commentary)

Substance P

The substance P receptor antagonist CP-99,994 reduces acute postoperative pain (Dionne et al). 1998;64:562-8

T

Tamoxifen

Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin (Kivistö et al). 1998;64:648-54

Tanzania

Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their *CYP2C19* genotype (Herrlin et al). 1998;64:391-401

Tension headache; see Headache

Testosterone

A model for the turnover of dihydrotestosterone in the presence of the irreversible 5 α -reductase inhibitors G1198745 and finasteride (Olsson Gisleskog et al). 1998;64:636-47

Thailand

The use of two estrogen preparations (a combined contraceptive pill versus conjugated estrogen cream) intravaginally to treat urogenital symptoms in postmenopausal Thai women: a comparative study (Chompootaweep et al). 1998;64:204-10

Thalidomide

Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone (Trapnell et al). 1998;64:597-602

Thiopurine methyltransferase

Isolation of a human thiopurine S-methyltransferase (TPMT) complementary DNA with a single nucleotide transition A719G (*TPMT*3C*) and its association with loss of TPMT protein and catalytic activity in humans (Loennechen et al). 1998;64:46-51

Thyrotropin alfa

Thyrotropin alfa (USAN List No. 406). 1998;64:132

Tianeptine

Neuropharmacologic treatment of bronchial asthma with the antidepressant tianeptine: a double-blind, crossover placebo-controlled study (Lechin et al). 1998;64:223-32

Time factors

Indirect-response model for the time course of leukopenia with anticancer drugs (Minami et al). 1998;64:511-21

Time course of enzyme induction in humans: effect of pentobarbital on nortriptyline metabolism (von Bahr et al). 1998;64:18-26

Toborinone

Toborinone (USAN List No. 410). 1998;64:576

Toremifene

Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin (Kivistö et al). 1998;64:648-54

Trafermin

Trafermin (USAN List No. 407). 1998;64:235

Triazolam

Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences (Greenblatt et al). 1998;64:278-85

Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences (Greenblatt et al). 1998;64:237-47

U

Ulcer

Ant ulcer drug prescribing in hospital successfully influenced by "immediate concurrent feedback" (Kumana et al). 1998;64:569-74

United States Adopted Names Council

USAN Council. 1998;64:131-2, 234-6, 351-2, 468-9, 576-7, 695-6

Urodilatin

Hemodynamic effects of continuous urodilatin infusion: a dose-finding study (Dorner et al). 1998;64:322-30

Metabolism and action of urodilatin infusion in healthy volunteers (Carstens et al). 1998;64:73-86

Urogenital diseases

The use of two estrogen preparations (a combined contraceptive pill versus conjugated estrogen cream) intravaginally to treat urogenital symptoms in postmenopausal Thai women: a comparative study (Chompootaweep et al). 1998;64:204-10

Urokinase alfa

Urokinase alfa (USAN List No. 406). 1998;64:131

V

Vaginal administration; see Administration, vaginal**Vasodilation**

Amiodarone causes endothelium-dependent vasodilation in human hand veins *in vivo* (Grossmann et al). 1998;64:302-11

Veins

Amiodarone causes endothelium-dependent vasodilation in human hand veins *in vivo* (Grossmann et al). 1998;64:302-11

Verapamil

Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations (Kantola et al). 1998;64:177-82

W

Warfarin

Interaction between warfarin and 5-fluorouracil, not between warfarin and levamisole (Brown). 1998;64:233 (Letter)

Watercress

Inhibition of chlorzoxazone metabolism, a clinical probe for CYP2E1, by a single ingestion of watercress (Leclercq et al). 1998;64:144-9

Z

Zaleplon

Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo (Greenblatt et al). 1998;64:553-61

Zidovudine

Concentration-controlled zidovudine therapy (Fletcher et al). 1998;64:331-8

Zolpidem

Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo (Greenblatt et al). 1998;64:553-61

Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole (Greenblatt et al). 1998;64:661-71

